Drug intelligence / Profile preview

mi-TUMEXim

Development stage: Preclinical
Lead developer: Multimmune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

mi-TUMEXim is a preclinical-stage monoclonal antibody developed by Multimmune that specifically targets membrane-bound Heat Shock Protein 70 (mHsp70). Unlike cytosolic Hsp70, mHsp70 is exclusively expressed on the surface of various tumor cells and their metastases, but not on normal tissues, making it a highly specific biomarker for cancer. mi-TUMEXim is designed for multiple applications, including fluorescence-guided imaging (conjugated with Cy5.5) for intraoperative tumor detection and potential drug delivery. By binding to mHsp70, the antibody enables real-time visualization of colon carcinoma and other solid tumors, facilitating more precise surgical resection and diagnostic assessment.

Other names: mi-TUMEXim

Targets

HSPA1A (HSP70-1A)

Beyond the preview

Go deeper on mi-TUMEXim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mi-TUMEXim.

Explore the full profile